[{"indications": "Indications\u00a0prophylaxis of angina; adjunct in congestive\r\nheart failure", "name": "ISOSORBIDE MONONITRATE Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.6 Nitrates, calcium-channel blockers, and other antianginal drugs", "2.6.1 Nitrates", "ISOSORBIDE MONONITRATE", "Modified release"], "cautions": "Cautions\u00a0see under Glyceryl Trinitrate", "side-effects": "Side-effects\u00a0see under Glyceryl Trinitrate", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2665.htm", "doses": ["Initially 20\u00a0mg 2\u20133 times daily or 40\u00a0mg\r\ntwice daily (10\u00a0mg twice daily in those who have not previously received\r\nnitrates); up to 120\u00a0mg daily in divided doses if required", "Name[Imdur\u00ae (AstraZeneca)] Durules\u00ae (= tablets m/r), yellow,\r\nf/c, scored, isosorbide mononitrate 60\u00a0mg, net\r\nprice 28-tab pack = \u00a310.50. \r\n    Label:\r\n    25Dose\u00a0prophylaxis of angina, 1 tablet in the morning (half a\r\ntablet if headache occurs), increased to 2 tablets in the morning\r\nif required"], "pregnancy": "Pregnancy\u00a0manufacturers advise avoid unless potential benefit\r\noutweighs risk"}, {"indications": "Indications\u00a0prophylaxis of angina; adjunct in congestive\r\nheart failure", "name": "ISOSORBIDE MONONITRATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.6 Nitrates, calcium-channel blockers, and other antianginal drugs", "2.6.1 Nitrates", "ISOSORBIDE MONONITRATE"], "cautions": "Cautions\u00a0see under Glyceryl Trinitrate", "side-effects": "Side-effects\u00a0see under Glyceryl Trinitrate", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2657.htm", "doses": ["Initially 20\u00a0mg 2\u20133 times daily or 40\u00a0mg\r\ntwice daily (10\u00a0mg twice daily in those who have not previously received\r\nnitrates); up to 120\u00a0mg daily in divided doses if required"], "pregnancy": "Pregnancy\u00a0manufacturers advise avoid unless potential benefit\r\noutweighs risk"}]